D
Doron Therapeutics
Biologic therapies advancing osteoarthritis treatment with potent anti-inflammatory and regenerative capabilities
About Doron Therapeutics
Doron Therapeutics is a clinical stage biotechnology company focused on developing innovative treatments for osteoarthritis. The company specializes in a Phase 3 ready, intra-articular biologic drug derived from placental tissue, designed to deliver significant anti-inflammatory, tissue protective, and regenerative benefits. Doron Therapeutics primarily serves patients suffering from osteoarthritis, a progressive and degenerative joint disease. Operating in the biotechnology and healthcare market, the company employs a business model centered around the development and commercialization of advanced biologic therapies. Revenue generation is anticipated through successful clinical trials and eventual market approval, leading to sales of their lead product. The company was spun off from Bioventus in 2023, with Bioventus retaining a minority shareholder position. Despite financial challenges faced by Bioventus, Doron Therapeutics continues to advance its pipeline with a robust clinical database supporting its Phase 3 clinical study. Key management has successfully led the completion of Phase 2 studies, positioning the company as a leading player in osteoarthritis treatment.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2024 | $11M | $44M | SPRIM Global Investments | ↗ |
Growth signals
Latest recorded traffic for Doron Therapeutics is 280 monthly website visits, down 74.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Doron Therapeutics in the Chapel Hill ecosystem
The Doron Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
SPRIM Global Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Doron Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Doron Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









